Study of Genetic and Biomarker Factors in Heart Failure Patients Using Data from the Swedish National Heart Failure Registry

What this Trial Is About

This research aims to study heart failure by linking a large national heart failure registry in Sweden, called SwedeHF, with a high-quality biobank. The registry collects data on patients diagnosed with heart failure based on clinical judgment, regardless of their hearts ejection fraction. The study focuses on understanding the genetic influence and identifying new biomarkers that could inform heart failure management. It is observational and involves a large number of patients from multiple hospitals. University hospitals with access to central biobanking will collect samples such as blood plasma, whole blood, and urine from registered patients. These samples will enable detailed genetic, proteomic, metabolomic, and biomarker analyses. The biobank is linked to the registry data, creating a valuable resource for future research on heart failure. The study will observe differences between patients who respond to guideline-directed medical therapy and those who do not over periods of 2 and 5 years. Participants provide informed consent and are registered in SwedeHF. Researchers will analyze clinical data alongside biological samples to identify predictors of treatment response, morbidity, and mortality. Outcomes include identifying responders to therapy and differences in health outcomes over time. This ongoing study will continue through 2030, providing long-term data to support heart failure research and improve understanding of treatment effects and patient outcomes.

Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers